Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses

Abstract

Non-tuberculous mycobacterioses comprise a group of diseases caused by mycobacteria which do not belong to the Mycobacterium (M.) tuberculosis-complex and are not ascribed to M. leprae. These mycobacteria are characterized by a broad variety as to environmental distribution and adaptation. Some of the species may cause specific diseases, especially in patients with underlying immunosuppressive diseases, chronic pulmonary diseases or genetic predisposition, respectively. Worldwide, a rising prevalence and significance of non-tuberculous mycobacterioses is recognized. The present recommendations summarise current aspects of epidemiology, pathogenesis, clinical aspects, diagnostics – especially microbiological methods including susceptibility testing –, and specific treatment for the most relevant species. Diagnosis and treatment of non-tuberculous mycobacterioses during childhood and in HIV-infected individuals are described in separate chapters.

Zusammenfassung

Die nichttuberkulösen Mykobakteriosen umfassen eine Gruppe von Erkrankungen, die von Mykobakterien verursacht werden, die nicht dem Mycobacterium (M.) tuberculosis-Komplex und nicht M. leprae zugerechnet werden und durch eine breite Vielfalt in Hinsicht auf ihr Vorkommen und ihre Anpassungen an spezifische Umweltbedingungen charakterisiert sind. Einige Spezies können definierte Krankheitsbilder insbesondere bei Patienten mit systemischer Immunsuppression, vorbestehenden Lungenerkrankungen oder genetisch bedingter erhöhter Empfänglichkeit hervorrufen. Weltweit wird eine Zunahme der Prävalenz und der Bedeutung dieser Erregergruppe beobachtet. Die vorliegenden Empfehlungen fassen aktuelle Aspekte der Epidemiologie, der Pathogenese, Klinik, Diagnostik einschließlich mikrobiologischer Diagnostik und Resistenztestung sowie der speziesabhängigen Therapie bei nicht-tuberkulösen Mykobakteriosen zusammen. Außerdem werden die besonderen Aspekte der Diagnostik und Therapie im Kindesalter und bei HIV-infizierten Patienten dargestellt.

^* Overall responsibility

^** Responsible for individual chapter

• References

• 1 Griffith DE, Aksamit T, Brown-Elliott BA et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med 2007; 175: 367-416
• 2 Van Ingen J, Wagner D. Epidemiology of nontuberculous mycobacterial disease in Germany and worldwide. Pneumol 2011; 396-403
• 3 Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med 2013; 34: 87-94
• 4 American Thoracic Society. Mycobacterioses and the acquired immunodeficiency syndrome. Joint Position Paper of the American Thoracic Society and the Centers for Disease Control. Am Rev Respir Dis 1987; 136: 492-496
• 5 Radenbach KL, Loddenkemper R. Zunehmende Bedeutung der Lungenkrankheiten durch sogenannte atypische Mykobakterien. Öffentl Ges-Wes 1985; 47: 459-462
• 6 Schütt-Gerowitt H. On the development of mycobacterial infections. II. Changing mycobacterial infection spectrum in the Cologne area 1983–1993. Zent Bakteriol 1985; 225-238
• 7 Schönfeld N, Schaberg T, Loddenkemper R. Neue Entwicklungen bei nicht-tuberkulösen Mykobakteriosen. Teil 1: Erkrankungen bei Patienten ohne HIV-Infektion. Pneumologie 1996; 313-322
• 8 Falkinham JO. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002; 23: 529-551
• 9 Adjemian J, Olivier KN, Seitz AE et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012; 185: 881-886
• 10 Adjemian J, Olivier KN, Seitz AE et al. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012; 186: 553-558
• 11 Schulze-Röbbecke R, Janning B, Fischeder R. Occurrence of mycobacteria in biofilm samples. Tuber Lung Dis 1992; 73: 141-144
• 12 Leite CQ, Anno IS, Leite SR et al. Isolation and identification of mycobacteria from livestock specimens and milk obtained in Brazil. Mem Inst Oswaldo Cruz 2003; 98: 319-323
• 13 Jordão Jr CM, Lopes FCM, David S et al. Detection of nontuberculous mycobacteria from water buffalo raw milk in Brazil. Food Microbiol 2009; 26: 658-661
• 14 Eltholth MM, Marsh VR, Van Winden S et al. Contamination of food products with Mycobacterium avium paratuberculosis: a systematic review. J Appl Microbiol 2009; 107: 1061-1071
• 15 Shankar H, Singh SV, Singh PK et al. Presence, characterization, and genotype profiles of Mycobacterium avium subspecies paratuberculosis from unpasteurized individual and pooled milk, commercial pasteurized milk, and milk products in India by culture, PCR, and PCR-REA methods. Int J Infect Dis 2010; 14: e121-126
• 16 Daley CL, Griffith DE. Pulmonary non-tuberculous mycobacterial infections. Int J Tuberc Lung Dis 2010; 14: 665-671
• 17 Marras TK, Wallace RJ, Koth LL et al. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 2005; 127: 664-671
• 18 Hanak V, Golbin JM, Ryu JH. Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis. Mayo Clin Proc 2007; 82: 812-816
• 19 Hartman TE, Jensen E, Tazelaar HD et al. CT findings of granulomatous pneumonitis secondary to Mycobacterium avium-intracellulare inhalation: “hot tub lung”. AJR Am J Roentgenol 2007; 188: 1050-1053
• 20 Tillie-Leblond I, Grenouillet F, Reboux G et al. Hypersensitivity pneumonitis and metalworking fluids contaminated by mycobacteria. Eur Respir J 2011; 37: 640-647
• 21 Marras TK, Chedore P, Ying AM et al. Isolation prevalence of pulmonary non tuberculous mycobacteria in Ontario, 1997 – 2003. Thorax 2007; 62: 661-666
• 22 Prevots DR, Shaw PA, Strickland D et al. Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery Systems. Am J Respir Crit Care Med 2010; 182: 970-976
• 23 Winthrop KL, McNelley E, Kendall B et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010; 182: 977-982
• 24 Thomson RM. NTM working group at Queensland TB Control Centre, Queensland Mycobacterial Reference Laboratory. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010; 16: 1576-1583
• 25 Lai CC, Tan CK, Chou CH et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000 – 2008. Emerg Infect Dis 2010; 16: 294-296
• 26 Moore JE, Kruijshaar ME, Ormerod LP et al. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995 – 2006. BMC Public Health 2010; 10: 612
• 27 van Ingen J, Bendien SA, de Lange WCM et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009; 64: 502-506
• 28 van Ingen J, Hoefsloot W, Dekhuijzen PNR et al. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis 2010; 14: 1176-1180
• 29 Andréjak C, Thomsen VØ, Johansen IS et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181: 514-521
• 30 Jankovic M, Samarzija M, Sabol I et al. Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. Int J Tuberc Lung Dis 2013; 17: 836-841
• 31 Koh WJ. Epidemiology of pulmonary non-tuberculous mycobacterial infections: need to identify environmental sources. Int J Tuberc Lung Dis 2013; 17: 713
• 32 Jones D, Havlir DV. Nontuberculous mycobacteria in the HIV infected patient. Clin Chest Med 2002; 23: 665-674
• 33 Henry MT, Inamdar L, O’Riordain D et al. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J 2004; 23: 741-746
• 34 Schönfeld N. The mycobacterial mystery. Eur Respir J 2006; 28: 1076-1078
• 35 Behr MA, Falkinham JO. Molecular epidemiology of nontuberculous mycobacteria. Future Microbiol 2009; 4: 1009-1020
• 36 van Soolingen D, van Ingen J. On the road to unravelling the aetiology of non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis 2012; 16: 1279
• 37 Simons S, van Ingen J, Hsueh P-R et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011; 17: 343-349
• 38 Hoefsloot W, van Ingen J, Andrejak C et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013; 42: 1604-1613
• 39 Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119: 107-159
• 40 Radenbach K. Diagnostische und therapeutische Fortschritte bei nichttuberkulösen Mykobakterien. Prax Klin Pneumol 1985; 39: 43-49
• 41 Billinger ME, Olivier KN, Viboud C et al. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998 – 2005. Emerg Infect Dis 2009; 15: 1562-1569
• 42 Iseman MD, Marras TK. The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 2008; 178: 999-1000
• 43 Szabó I, Kiss KK, Várnai I et al. Epidemic pulmonary infection associated with Mycobacterium xenopi indigenous in sewage-sludge. Acta Microbiol Acad Sci Hung 1982; 29: 263-266
• 44 Bryant JM, Grogono DM, Greaves D et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381: 1551-1560
• 45 Matthiessen W, Schmidt C, Rüsch-Gerdes S et al. [Significance of local and general risk factors for the pathogenesis of pulmonary, non-tuberculous mycobacteriosis in non-AIDS patients]. Pneumologie 2010; 64: 281-290
• 46 Braun E, Sprecher H, Davidson S et al. Epidemiology and clinical significance of non-tuberculous mycobacteria isolated from pulmonary specimens. Int J Tuberc Lung Dis 2013; 17: 96-99
• 47 Sexton P, Harrison AC. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008; 31: 1322-1333
• 48 Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med 2013; 34: 110-123
• 49 Prince DS, Peterson DD, Steiner RM et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321: 863-868
• 50 Kartalija M, Ovrutsky AR, Bryan CL et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013; 187: 197-205
• 51 Fowler CJ, Olivier KN, Leung JM et al. Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med 2013; 187: 1374-1381
• 52 Vesenbeckh S, Wagner S, Mauch H et al. [Pathogenicity of Mycobacterium kansasii]. Pneumologie 2014; 68: 526-531
• 53 Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 1994; 73: 103-109
• 54 Fritscher LG, Marras TK, Bradi AC et al. Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study. Chest 2011; 139: 23-27
• 55 Schönfeld N, Matthiessen W, Grassot A. Komplikationen der pulmonalen Beteiligung beim M. Bechterew. Aktuelle Radiol 1991; 1: 249-252
• 56 Kim RD, Greenberg DE, Ehrmantraut ME et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178: 1066-1074
• 57 Andréjak C, Nielsen R, Thomsen VØ et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68: 256-262
• 58 Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101: 1605-1609
• 59 Yu JA, Pomerantz M, Bishop A et al. Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur J Cardio-Thorac Surg 2011; 40: 671-675
• 60 Koh W-J, Lee JH, Kwon YS et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest 2007; 131: 1825-1830
• 61 Forschbach G. [Non-tuberculous infections caused by Mycobacteria]. Internist 1975; 16: 393-400
• 62 Olivier KN, Weber DJ, Wallace RJ et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 828-834
• 63 Roux A-L, Catherinot E, Ripoll F et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol 2009; 47: 4124-4128
• 64 Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013; 34: 124-134
• 65 Tomashefski JF, Stern RC, Demko CA et al. Nontuberculous mycobacteria in cystic fibrosis. An autopsy study. Am J Respir Crit Care Med 1996; 154: 523-528
• 66 Fowler SJ, French J, Screaton NJ et al. Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics. Eur Respir J 2006; 28: 1204-1210 Erratum in Eur Respir J 2007; 29: 614 – 615
• 67 Brown-Elliott BA, Mann LB, Hail D et al. Antimicrobial susceptibility of nontuberculous mycobacteria from eye infections. Cornea 2012; 31: 900-906
• 68 Bennett SN, Peterson DE, Johnson DR et al. Bronchoscopy-associated Mycobacterium xenopi pseudoinfections. Am J Respir Crit Care Med 1994; 150: 245-250
• 69 Sousa TS, Matherne RJ, Wilkerson MG. Case report: cutaneous nontuberculous mycobacterial abscesses associated with insulin injections. J Drugs Dermatol 2010; 9: 1439-1442
• 70 Song Y, Wu J, Yan H et al. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. Nephrol Dial Transplant 2012; 27: 1639-1644
• 71 Winthrop KL, Abrams M, Yakrus M et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med 2002; 346: 1366-1371
• 72 LeBlanc PM, Hollinger KA, Klontz KC. Tattoo ink-related infections -- awareness, diagnosis, reporting, and prevention. N Engl J Med 2012; 367: 985-987
• 73 Lewis FMT, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis 2003; 37: 390-397
• 74 Walsh DS, Portaels F, Meyers WM. Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin 2011; 29: 1-8
• 75 Kirk O, Gatell JM, Mocroft A et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162: 865-872
• 76 Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [Internet]. Verfügbar unter: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf
• 77 Rutsky EA, Rostand SG. Mycobacteriosis in patients with chronic renal failure. Arch Intern Med 1980; 140: 57-61
• 78 Sartori FG, Leandro LF, Montanari LB et al. Isolation and identification of environmental mycobacteria in the waters of a hemodialysis center. Curr Microbiol 2013; 67: 107-111
• 79 Daley CL. Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant 2009; 14: 619-624
• 80 Ferreira J, Grochowsky J, Krakower D et al. Mycobacterium marinum: an increasingly common opportunistic infection in patients on infliximab. Am J Gastroenterol 2012; 107: 1268-1269
• 81 Kump PK, Högenauer C, Wenzl HH et al. A case of opportunistic skin infection with Mycobacterium marinum during adalimumab treatment in a patient with Crohn’s disease. J Crohns Colitis 2013; 7: e15-18
• 82 Winthrop KL, Chang E, Yamashita S et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15: 1556-1561
• 83 Iseman MD. Mycobacterial infections in the era of modern biologic agents. Am J Med Sci 2011; 341: 278-280
• 84 Dirac MA, Horan KL, Doody DR et al. Environment or host? A case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012; 186: 684-691
• 85 Rupp J, Schaaf B. Infektionen mit nichttuberkulösen Mykobakterien bei Patienten mit Immundefekten. Pneumologe 2011; 8: 402-407
• 86 Colombo RE, Hill SC, Claypool RJ et al. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2010; 137: 629-634
• 87 Vinh DC, Patel SY, Uzel G et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115: 1519-1529
• 88 Cassidy PM, Hedberg K, Saulson A et al. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49: e124-129
• 89 Tortoli E. The new mycobacteria: an update. FEMS Immunol Med Microbiol 2006; 48: 159-178
• 90 Taillard C, Greub G, Weber R et al. Clinical implications of Mycobacterium kansasii species heterogenecity: Swiss National Survey. J Clin Microbiol 2003; 41: 1240-1244
• 91 Lindeboom JA, Bruijnesteijn van Coppenraet LES, van Soolingen D et al. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev 2011; 24: 701-717
• 92 O’Connell ML, Birkenkamp KE, Kleiner DE et al. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest 2012; 141: 1203-1209
• 93 Hauer B, Loddenkemper R, Detjen A et al. [Interferon-gamma assays -- description and assessment of a new tool in the diagnosis of tuberculosis]. Pneumologie 2006; 60: 29-44
• 94 Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008; 8: 147-152
• 95 van Ingen J. Diagnosis of nontuberculous mycobacterial infections. Semin Respir Crit Care Med 2013; 34: 103-109
• 96 Roth A, Reischl U, Schönfeld N et al. Mycobacterium heckeshornense sp. nov., A new pathogenic slowly growing Mycobacterium sp. Causing cavitary lung disease in an immunocompetent patient. J Clin Microbiol 2000; 38: 4102-4107
• 97 Kendall BA, Varley CD, Hedberg K et al. Isolation of non-tuberculous mycobacteria from the sputum of patients with active tuberculosis. Int J Tuberc Lung Dis 2010; 14: 654-656
• 98 Damaraju D, Jamieson F, Chedore P et al. Isolation of non-tuberculous mycobacteria among patients with pulmonary tuberculosis in Ontario, Canada. Int J Tuberc Lung Dis 2013; 17: 676-681
• 99 Koh WJ, Yu CM, Suh GY et al. Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum. Int J Tuberc Lung Dis 2006; 10: 1001-1007
• 100 Greinert U, Lotz W. Pulmonale Infektionen durch nichttuberkulöse Mykobakterien. Radiologische Aspekte und Differenzialdiagnose. Pneumologe 2011; 8: 404-411
• 101 Richter E, Brown-Elliott BA, Wallace RJJ. Mycobacterium: Laboratory Characteristics of Slowly Growing Mycobacteria. In: Manual of clinical microbiology ASM Press; 2011
• 102 DIN 58943-4 Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 4: Primärproben zur Tuberkulose- und Mykobakteriosediagnostik – Qualitative und quantitative Anforderungen, Gewinnung, Transport und Aufbewahrung; Text Deutsch und Englisch (DIN 58943-4:2009).
• 103 Falkinham JO. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009; 107: 356-367
• 104 Del Giudice G, Iadevaia C, Santoro G et al. Nontuberculous mycobacterial lung disease in patients without HIV infection: a retrospective analysis over 3 years. Clin Respir J 2011; 5: 203-210
• 105 DIN 58943-32 Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 32: Mikroskopische Methoden zum Nachweis von Mykobakterien (DIN 58943-32: 1995).
• 106 Richter E, Beer J, Diel R. Tuberkulose Mykobakteriose. Podbielski A, Mauch H, Herrmann H, et al. Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. 2. Auflage. Urban & Fischer in Elsevier; 2010
• 107 Richter E, Rüsch-Gerdes S, Niemann S et al. Detection, identification, and treatment of a novel, non-cultivable Mycobacterium species in an HIV patient. AIDS Lond Engl 2000; 14: 1667-1668
• 108 DIN 58943-3 Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 3: Kulturelle Methoden zum Nachweis von Mykobakterien (DIN 58943-3: 1996).
• 109 Hanna BA, Ebrahimzadeh A, Elliott LB et al. Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. J Clin Microbiol 1999; 37: 748-752
• 110 Tortoli E, Cichero P, Piersimoni C et al. Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study. J Clin Microbiol 1999; 37: 3578-3582
• 111 Richter E, Rüsch-Gerdes S, Hillemann D et al. Evaluation of the GenoType Mycobacterium Assay for identification of mycobacterial species from cultures. J Clin Microbiol 2006; 44: 1769-1775
• 112 Russo C, Tortoli E, Menichella D. Evaluation of the new GenoType Mycobacterium assay for identification of mycobacterial species. J Clin Microbiol 2006; 44: 334-339
• 113 Lee AS, Jelfs P, Sintchenko V et al. Identification of non-tuberculous mycobacteria: utility of the GenoType Mycobacterium CM/AS assay compared with HPLC and 16S rRNA gene sequencing. J Med Microbiol 2009; 58: 900-904
• 114 Mäkinen J, Sarkola A, Marjamäki M et al. Evaluation of genotype and LiPA MYCOBACTERIA assays for identification of Finnish mycobacterial isolates. J Clin Microbiol 2002; 40: 3478-3481
• 115 Tortoli E, Mariottini A, Mazzarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: improved reverse hybridization multiple DNA probe assay for mycobacterial identification. J Clin Microbiol 2003; 41: 4418-4420
• 116 Kirschner P, Springer B, Vogel U et al. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory. J Clin Microbiol 1993; 31: 2882-2889
• 117 Roth A, Fischer M, Hamid ME et al. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. J Clin Microbiol 1998; 36: 139-147
• 118 Han XY, Pham AS, Tarrand JJ et al. Rapid and accurate identification of mycobacteria by sequencing hypervariable regions of the 16S ribosomal RNA gene. Am J Clin Pathol 2002; 118: 796-801
• 119 Pauls RJ, Turenne CY, Wolfe JN et al. A high proportion of novel mycobacteria species identified by 16S rDNA analysis among slowly growing AccuProbe-negative strains in a clinical setting. Am J Clin Pathol 2003; 120: 560-566
• 120 Woods GL, Brown-Elliot B, Conville PS et al. Susceptibility testing of mycobacteria, norcardiae, and other aeroboic actinomycetes: approved standard. Clinical: Clinical and Laboratory Standards Institute; 2011
• 121 Scarparo C, Ricordi P, Ruggiero G et al. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol 2004; 42: 1109-1114
• 122 Rüsch-Gerdes S, Pfyffer GE, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-692
• 123 Lucke K, Hombach M, Friedel U et al. Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST. J Antimicrob Chemother 2012; 67: 154-158
• 124 Hombach M, Somoskövi A, Hömke R et al. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST. Int J Med Microbiol 2013; 303: 270-276
• 125 DIN 58943-8 Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 8: Empfindlichkeitsprüfung von Tuberkulosebakterien gegen Chemotherapeutika (DIN 58943-8: 2009).
• 126 Nash KA, Brown-Elliott BA, Wallace RJ. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-1376
• 127 Bastian S, Veziris N, Roux A-L et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-781
• 128 van Ingen J, Boeree MJ, van Soolingen D et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15: 149-161
• 129 Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995; 39: 2625-2630
• 130 van Ingen J, Egelund EF, Levin A et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012; 186: 559-565
• 131 Koh W-J, Jeong B-H, Jeon K et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012; 186: 797-802
• 132 Schluger NW. Treatment of pulmonary Mycobacterium avium complex infections: do drug levels matter?. Am J Respir Crit Care Med 2012; 186: 710-711
• 133 Philley JV, Griffith DE. Management of nontuberculous mycobacterial (NTM) lung disease. Semin Respir Crit Care Med 2013; 34: 135-142
• 134 Ballarino GJ, Olivier KN, Claypool RJ et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009; 103: 1448-1455
• 135 Schaberg T, Bauer T, Castell S et al. Empfehlungen zur Therapie, Chemoprävention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter. Pneumologie 2012; 66: 133-171
• 136 van Ingen J, Verhagen AFTM, Dekhuijzen PNR et al. Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. Int J Tuberc Lung Dis 2010; 14: 99-105
• 137 Pomerantz M, Madsen L, Goble M et al. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991; 52: 1108-1111; discussion 1112
• 138 Nelson KG, Griffith DE, Brown BA et al. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg 1998; 66: 325-330
• 139 Junghanss T, Um Boock A, Vogel M et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 2009; 3: e380
• 140 Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2012; 25: 218-227
• 141 Chaisson RE, Moore RD, Richman DD et al. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis 1992; 146: 285-289
• 142 Nightingale SD, Byrd LT, Southern PM et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082-1085
• 143 Lawn SD, Bekker L-G, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-373
• 144 Corbett EL, Blumberg L, Churchyard GJ et al. Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. Am J Respir Crit Care Med 1999; 160: 15-21
• 145 Bloch KC, Zwerling L, Pletcher MJ et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129: 698-704
• 146 Cattamanchi A, Nahid P, Marras TK et al. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 2008; 133: 875-880
• 147 Phillips P, Bonner S, Gataric N et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41: 1483-1497
• 148 Shelburne SA, Hamill RJ, Rodriguez-Barradas MC et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81: 213-227
• 149 Meintjes G, Wilkinson RJ, Morroni C et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390
• 150 Gordin FM, Cohn DL, Sullam PM et al. Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J Infect Dis 1997; 176: 126-132
• 151 Chaisson RE, Benson CA, Dube MP et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121: 905-911
• 152 Benson CA, Williams PL, Currier JS et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis Off Publ Infect Dis Soc Am 2003; 37: 1234-1243
• 153 Dunne M, Fessel J, Kumar P et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1245-1252
• 154 Havlir DV, Dubé MP, Sattler FR et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335: 392-398
• 155 Pierce M, Crampton S, Henry D et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-391
• 156 El-Sadr WM, Burman WJ, Grant LB et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342: 1085-1092
• 157 Aberg JA, Williams PL, Liu T et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis 2003; 187: 1046-1052
• 158 Haas WH. Diagnostik und Therapie von Erkrankungen durch nichttuberkulöse Mykobakterien im Kindesalter. Kinder- und Jugendarzt 2005; 403-408
• 159 Katila ML, Brander E, Backman A. Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood. Tubercle 1987; 68: 291-296
• 160 Haverkamp MH, Lindeboom JA, de Visser AW et al. Nontuberculous mycobacterial cervicofacial lymphadenitis in children from the multicenter, randomized, controlled trial in The Netherlands: relevance of polymorphisms in candidate host immunity genes. Int J Pediatr Otorhinolaryngol 2010; 74: 752-754
• 161 Thegerström J, Romanus V, Friman V et al. Mycobacterium avium lymphadenopathy among children, Sweden. Emerg Infect Dis 2008; 14: 661-663
• 162 Blyth CC, Best EJ, Jones CA et al. Nontuberculous mycobacterial infection in children: a prospective national study. Pediatr Infect Dis J 2009; 28: 801-805
• 163 Reuss AM, Wiese-Posselt M, Weissmann B et al. Incidence rate of nontuberculous mycobacterial disease in immunocompetent children: a prospective nationwide surveillance study in Germany. Pediatr Infect Dis J 2009; 28: 642-644
• 164 Casanova JL. Mendelian susceptibility to mycobacterial infection in man. Swiss Med Wkly 2001; 131: 445-454
• 165 Reichenbach J, von Bernuth H. Genetisch bedingte Defekte der angeborenen Immunität - Erhöhte Anfälligkeit für mykobakterielle Infektionen, für invasive bakterielle Infektionen und für Herpes-simplex-Enzephalitis. Kinder- Jugendmed 2008; 8: 171-178
• 166 Fauroux B, Delaisi B, Clément A et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997; 16: 354-358
• 167 Esther CR, Henry MM, Molina PL et al. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005; 40: 39-44
• 168 Weigl JA, Haas WH. Postoperative Mycobacterium avium osteomyelitis confirmed by polymerase chain reaction. Eur J Pediatr 2000; 159: 64-69
• 169 Hoefsloot W, van Ingen J, de Lange WCM et al. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J 2009; 34: 926-931
• 170 Magdorf K, Bialek R, Detjen AK. Tuberkulose und nicht tuberkulöse mykobakterielle Krankheiten. In: DGPI Handbuch Infektionen bei Kindern und Jugendlichen. Stuttgart: Thieme; 2009
• 171 Haas W. Erkrankungen durch Umweltmykobakterien. In: Therapie der Krankheiten im Kindes-und Jugendalter. Berlin: Springer; 2004: 449-453
• 172 von Reyn C, Pozniak A, Haas W, Nichols G. Disseminated infection, cervical adenitis and other MAC infections. In: Pedley S, Bartram J, Rees G, et al., eds. Pathogenic mycobacteria in water: a guide to public health consequences, monitoring and management. London: IWA Publishing on behalf of the World Health Organization; 2004: 95-103
• 173 Detjen AK, Keil T, Roll S et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45: 322-328
• 174 Mazurek GH, Jereb J, Vernon A et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep 2010; 59: 1-25
• 175 Carvalho ACC, Codecasa L, Pinsi G et al. Differential diagnosis of cervical mycobacterial lymphadenitis in children. Pediatr Infect Dis J 2010; 29: 629-633
• 176 Lindeboom JA, Smets AMJB, Kuijper EJ et al. The sonographic characteristics of nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Radiol 2006; 36: 1063-1067
• 177 Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 2009; 15: 1351-1358; quiz 1544
• 178 Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20: 954-963
• 179 Schaad UB, Votteler TP, McCracken GH et al. Management of atypical mycobacterial lymphadenitis in childhood: a review based on 380 cases. J Pediatr 1979; 95: 356-360
• 180 Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES et al. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 44: 1057-1064
• 181 Lindeboom JA, Lindeboom R, Bruijnesteijn van Coppenraet ES et al. Esthetic outcome of surgical excision versus antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Infect Dis J 2009; 28: 1028-1030
• 182 Iversen RH, Illum P. Cervicofacial nontuberculous mycobacterial lymphadenitis in children. Dan Med J 2012; 59: A4349
• 183 Reuss A, Drzymala S, Hauer B. Langzeitverlauf und Therapieerfolg bei Lymphadenitiden durch nichttuberkulöse Mykobakterien bei Kindern in Deutschland [Internet]. Verfügbar unter: http://www.dgpi2012.de/media/PDFs/Abstractband_DGPI2012.pdf
• 184 Koh W-J, Jeong B-H, Jeon K et al. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. Chest 2012; 142: 1482-1488
• 185 Tortoli E, Rindi L, Garcia MJ et al. Proposal to elevate the genetic variant MAC-A, included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp.nov. Int J Syst Evol Microbiol 2004; 54: 1277-1285
• 186 Murcia MI, Tortoli E, Menendez MC et al. Mycobacterium colombiense sp. nov., a novel member of the Mycobacterium avium complex and description of MAC-X as a new ITS genetic variant. Int J Syst Evol Microbiol 2006; 56: 2049-2054
• 187 Bang D, Herlin T, Stegger M et al. Mycobacterium arosiense sp. nov., a slowly growing, scotochromogenic species causing osteomyelitis in an immunocompromised child. Int J Syst Evol Microbiol 2008; 58: 2398-2402
• 188 van Ingen J, Boeree MJ, Kösters K et al. Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov. Int J Syst Evol Microbiol 2009; 59: 2277-2282
• 189 Thorel MF, Krichevsky M, Lévy-Frébault VV. Numerical taxonomy of mycobactin-dependent mycobacteria, emended description of Mycobacterium avium, and description of Mycobacterium avium subsp.avium subsp. nov., Mycobacterium avium subsp. paratuberculosis subsp. nov., and Mycobacterium avium subsp. silvaticum subsp. nov. Int J Syst Bacteriol 1990; 40: 254-260
• 190 Mijs W, de Haas P, Rossau R et al. Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. avium for bird-type isolates and “M. avium subsp. hominissuis” for the human/porcine type of M. avium. Int J Syst Evol Microbiol 2002; 52: 1505-1518
• 191 Dhama K, Mahendran M, Tiwari R et al. Tuberculosis in Birds: Insights into the Mycobacterium avium Infections. Vet Med Int 2011; 2011: 712369
• 192 Sweeney RW, Collins MT, Koets AP et al. Paratuberculosis (Johne’s disease) in cattle and other susceptible species. J Vet Intern Med 2012; 26: 1239-1250
• 193 Over K, Crandall PG, O’Bryan CA et al. Current perspectives on Mycobacterium avium subsp.paratuberculosis, Johne’s disease, and Crohn’s disease: a review. Crit Rev Microbiol 2011; 37: 141-156
• 194 Kim S-Y, Lee S-T, Jeong B-H et al. Clinical significance of mycobacterial genotyping in Mycobacterium avium lung disease in Korea. Int J Tuberc Lung Dis 2012; 16: 1393-1399
• 195 Falkinham JO. Hospital water filters as a source of Mycobacterium avium complex. J Med Microbiol 2010; 59: 1198-1202
• 196 Lam PK, Griffith DE, Aksamit TR et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 173: 1283-1289
• 197 Shafran SD, Talbot JA, Chomyc S et al. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group. Clin Infect Dis 1998; 27: 1401-1405
• 198 Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14: 1039-1043
• 199 Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007; 101: 130-138
• 200 Kohno Y, Ohno H, Miyazaki Y et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob Agents Chemother 2007; 51: 4071-4076
• 201 Butler WR, O’Connor SP, Yakrus MA et al. Mycobacterium celatum sp. nov. Int J Syst Bacteriol 1993; 43: 539-548
• 202 Piersimoni C, Tortoli E, De Sio G. Disseminated infection due to Mycobacterium celatum in patient with AIDS. Lancet 1994; 344: 332
• 203 Bull TJ, Shanson DC, Archard LC et al. A new group (type 3) of Mycobacterium celatum isolated from AIDS patients in the London area. Int J Syst Bacteriol 1995; 45: 861-862
• 204 Piersimoni C, Zitti PG, Nista D et al. Mycobacterium celatum pulmonary infection in the immunocompetent: case report and review. Emerg Infect Dis 2003; 9: 399-402
• 205 Jun H-J, Lee NY, Kim J et al. Successful treatment of Mycobacterium celatum pulmonary disease in an immunocompetent patient using antimicobacterial chemotherapy and combined pulmonary resection. Yonsei Med J 2010; 51: 980-983
• 206 Böttger EC, Teske A, Kirschner P et al. Disseminated „Mycobacterium genavense“ infection in patients with AIDS. Lancet 1992; 340: 76-80
• 207 Hoefsloot W, van Ingen J, Peters EJG et al. Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases. Clin Microbiol Infect 2013; 19: 432-437
• 208 Krebs T, Zimmerli S, Bodmer T et al. Mycobacterium genavense infection in a patient with long-standing chronic lymphocytic leukaemia. J Intern Med 2000; 248: 343-348
• 209 Lorenzen J, Meyer-Olson D, Haubitz M et al. Infection with Mycobacterium genavense in a patient with systemic lupus erythematosus. Clin Rheumatol 2009; 28 (Suppl. 01) 39-41
• 210 Gößwald A. Klinik, Diagnostik, Therapie und Verlauf pulmonaler Infektionen durch nichttuberkulöse Mykobakterien bei HIV-negativen Patienten in Berlin 1986 – 1998. Berlin: Freie Universität; 2004
• 211 Griffith DE, Brown-Elliott BA, Wallace RJ et al. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37: 1178-1182
• 212 Abgueguen P, Rabier V, Mahaza C et al. Mycobacterium malmoense: an underestimated nontuberculous mycobacterium. Diagn Microbiol Infect Dis 2010; 66: 98-100
• 213 Murray MP, Laurenson IF, Hill AT et al. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection. Clin Infect Dis 2008; 47: 222-224
• 214 Esteban J, García-Pedrazuela M, Muñoz-Egea MC et al. Current treatment of nontuberculous mycobacteriosis: an update. Expert Opin Pharmacother 2012; 13: 967-986
• 215 Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis 2006; 25: 609-613
• 216 Aubry A, Chosidow O, Caumes E et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162: 1746-1752
• 217 Cheung JP, Fung B, Wong SS et al. Review article: Mycobacterium marinum infection of the hand and wrist. J Orthop Surg (Hong Kong) 2010; 18: 98-103
• 218 Narang R, Narang P, Jain AP et al. Disseminated disease caused by Mycobacterium simiae in AIDS patients: a report of three cases. Clin Microbiol Infect 2010; 16: 912-914
• 219 van Ingen J, Boeree MJ, de Lange WCM et al. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis 2008; 46: 1200-1205
• 220 Varadi RG, Marras TK. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis 2009; 13: 1210-1218
• 221 Adékambi T, Reynaud-Gaubert M, Greub G et al. Amoebal coculture of “Mycobacterium massiliense” sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42: 5493-5501
• 222 Adékambi T, Berger P, Raoult D et al. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp.nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56: 133-143
• 223 Leao SC, Tortoli E, Euzéby JP et al. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp.bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61: 2311-2313
• 224 Aitken ML, Limaye A, Pottinger P et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185: 231-232
• 225 Gilljam M, Scherstén H, Silverborn M et al. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010; 9: 272-276
• 226 Choi G-E, Shin SJ, Won C-J et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186: 917-925
• 227 Choi G-E, Min K-N, Won C-J et al. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. Antimicrob Agents Chemother 2012; 56: 3549-3555
• 228 Huang Y-C, Liu M-F, Shen G-H et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect 2010; 43: 401-406
• 229 Jarand J, Levin A, Zhang L et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52: 565-571
• 230 Griffith DE. UpToDate Topic 5347 Version 13.0: Rapidly growing mycobacterial infections in HIV-negative patients. Release 21.6, 2013